IAV H3 Subtype HA Specific Neutra™ Antibody Products

Are you grappling with the rapid antigenic drift of influenza A H3N2, leading to vaccine mismatch and compromised therapeutic efficacy? Creative Biolabs' IAV H3 Subtype HA Specific Neutra™ Antibody Products empower your research with high-precision, structure-guided antibodies. Leveraging advanced hybridoma and phage display platforms, we deliver rigorously validated neutralizing antibodies to dissect viral evolution, evaluate vaccine candidates, and fast-track the development of next-generation anti-influenza biologics.

Introduction to IAV H3 Subtype HA

Influenza A virus H3 subtype hemagglutinin (IAV H3 Subtype HA) is the principal surface glycoprotein responsible for viral attachment and host cell entry. As a major determinant of infectivity and a primary target of the host immune response, HA is the focal point for vaccine design and antiviral drug development. Its continuous evolution poses a persistent global public health challenge. IAV H3 Subtype HA is a type I transmembrane glycoprotein. It is synthesized as a precursor (HA0) that is cleaved by host proteases into two subunits, HA1 and HA2, a step critical for viral infectivity.

• Structural Insights

The HA trimer consists of a globular head domain (primarily HA1) containing the receptor-binding site (RBS) for sialic acids, and a stalk domain (HA2 and part of HA1). The head domain is immunodominant and hypervariable, driving antigenic drift. Conversely, the stalk domain is more conserved and is a key target for broadly neutralizing antibodies.

Fig.1 Endogenously observed mechanisms for optimizing HA–NA stoichiometry.¹

• Resistance and Signaling Pathways

The high mutation rate in the HA gene, especially in the head domain, facilitates antigenic drift, allowing the virus to evade pre-existing immunity. HA binding and membrane fusion can modulate host cell pathways, including the PI3K/Akt and NF-κB pathways, influencing viral replication and host inflammatory responses.

• Clinical Impact

IAV H3N2 is a major seasonal influenza strain associated with significant morbidity and mortality, particularly in elderly and high-risk populations. It causes respiratory illnesses ranging from mild upper respiratory tract infections to severe pneumonia and acute respiratory distress syndrome (ARDS).

• Antibodies Against IAV H3 Subtype HA

Neutralizing antibodies targeting HA are crucial for viral clearance. They primarily function by blocking receptor binding or inhibiting the conformational changes required for membrane fusion. Antibodies targeting the conserved stalk region offer promise for developing universal influenza vaccines and therapeutics.

Fig.2 Widely neutralizing epitopes located on hemagglutinin (HA).²

Applications of Anti-IAV H3 Subtype HA Neutralizing Antibodies

• Vaccine Efficacy and Immunogenicity Assessment

Anti-HA neutralizing antibodies are the gold-standard correlate of protection for influenza vaccines. Our Neutra™ antibodies are indispensable tools for standardized Hemagglutination Inhibition (HI) and Microneutralization (MN) assays. Researchers utilize them as reference standards to precisely quantify neutralizing antibody titers in serum samples from vaccinated individuals, directly evaluating vaccine immunogenicity and predicting protective efficacy against circulating H3N2 strains.

• Therapeutic Candidate Screening and Development

Monoclonal antibodies (mAbs) targeting conserved epitopes on IAV H3 Subtype HA represent a promising therapeutic strategy, especially for severe infections in immunocompromised patients. Our high-affinity antibodies serve as critical positive controls and benchmarking tools in discovery pipelines. They enable the screening and characterization of novel therapeutic mAbs by facilitating competitive binding assays, epitope mapping studies, and in vitro neutralization potency validation, accelerating the identification of lead candidates.

• Antigenic Characterization and Surveillance

Continuous monitoring of HA antigenic evolution is vital for global influenza surveillance. Our panel of strain-specific Neutra™ antibodies allows researchers to perform detailed antigenic cartography. By assessing cross-reactivity and neutralization escape patterns, these antibodies help identify emerging antigenic variants, inform WHO vaccine strain selection recommendations, and track the phylodynamic evolution of H3N2 viruses.

Our Anti-IAV H3 Subtype HA Neutralizing Antibodies

Creative Biolabs delivers premium antibody reagents designed for critical research and development:

• High Specificity and Affinity: Generated against carefully selected recombinant HA antigens, ensuring minimal cross-reactivity and robust binding.
• Extensive Validation: Functionally validated in key applications, including Microneutralization, Hemagglutination Inhibition, ELISA, and Western Blot.
• Broad Strain Coverage: Includes antibodies targeting classic and contemporary H3N2 strains, as well as those directed against conserved epitopes.
• Ready-to-Use Formats: Available in convenient formats for high-throughput screening and assay development, saving you valuable time and resources.

With over two decades of expertise in virology and antibody engineering, Creative Biolabs is your trusted partner in infectious disease research. We combine deep scientific knowledge with cutting-edge technology to provide antibodies you can rely on for accuracy and reproducibility. Our commitment is to support your work in understanding influenza pathogenesis, developing effective vaccines, and creating novel antiviral therapies. Contact our scientific team today to discuss your specific project requirements and request detailed product specifications.

References

1. Kosik, Ivan, and Jonathan W. Yewdell. "Influenza hemagglutinin and neuraminidase: Yin-Yang proteins coevolving to thwart immunity." Viruses 11.4 (2019): 346. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.3390/v11040346
2. Sangesland, Maya, and Daniel Lingwood. "Antibody focusing to conserved sites of vulnerability: The immunological pathways for 'universal'influenza vaccines." Vaccines 9.2 (2021): 125. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.3390/vaccines9020125